Karyopharm Therapeutics Inc. (KPTI)
NASDAQ
Closed
Oct 23, 2026
Day's Range
0.440052 wk Range
0.3100Overview - KPTI - Karyopharm Therapeutics Inc.
Key Statistics
Valuation
Enterprise Value
273.05M
P/E (Trailing)
-0.03
P/E (Forward)
-0.15
PEG Ratio
0.00065
Price / Sales (TTM)
0.06
Price / Book
-0.04
EV / EBITDA
-3.32
Profitability
Gross Margin
96.75%
Profit Margin
-153.28%
Operating Margin
-67.37%
Return on Assets
-47.61%
Return on Equity
66.92%
Ownership
Shares Outstanding
22.68M
Float
17.29M
Short % of Shares Outstanding
26.84%
Held by Insiders
4.65%
Held by Institutions
95.82%
Price stats
Beta
1.03
50-Day Avg
1.41
200-Day Avg
6.29
Analyst Consensus
5 analysts
Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - KPTI - Karyopharm Therapeutics Inc.
Peers - KPTI - Karyopharm Therapeutics Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- KPTINASDAQKaryopharm Therapeutics Inc.12.38MMarket Cap-1033.70%52-week change-0.03P/E (Trailing)-153.28%Profit Margin
- ARGXNASDAQArgenx SE51.51BMarket Cap-3.70%52-week change31.22P/E (Trailing)32.26%Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.31.02BMarket Cap-111.89%52-week change39.09P/E (Trailing)16.12%Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share22.13BMarket Cap-20.35%52-week change160.80P/E (Trailing)-63.63%Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.01BMarket Cap+16.49%52-week change18.23P/E (Trailing)70.84%Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.12.97BMarket Cap+15.27%52-week change-17.56P/E (Trailing)-97.02%Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.10.58BMarket Cap+1.57%52-week change147.76P/E (Trailing)2.14%Profit Margin
Profile Summary - KPTI - Karyopharm Therapeutics Inc.
About
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing therapies for cancer and other serious diseases. Karyopharm Therapeutics Inc. specializes in drugs that target nuclear export pathways, including selective inhibitor of nuclear export…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
